Pharma BD Deal Intelligence
Seawolf Therapeutics emerged from stealth with a $100 million Series A and simultaneously disclosed a multi-target DNA medicines research collaboration and exclusive license agreement with Sanofi. Seawolf is eligible for up to $1.2 billion across milestone payments plus tiered royalties on resulting products. The collaboration applies Seawolf's TRIDENT platform (Targeted RNA-Induced DNA Expression via Nuclear Translocation), which pairs a proprietary lipid nanoparticle with an immune-quiet DNA payload encoding a therapeutic transgene plus an auxiliary factor that facilitates nuclear access. Unlike viral DNA-delivery approaches, TRIDENT therapies are designed to be redosable. Named targets cover undisclosed therapies for bleeding disorders plus additional unnamed indications. The Series A was led by Versant, MPM BioImpact and Novartis Venture Fund, with participation from Eli Lilly, CRISPR Therapeutics, Sixty Degree Capital, Alexandria Venture Investments and Pathway to Cures.
← Browse all deals · How we score deals
More: 2026 deals · Sanofi S.A. deals